GE HealthCare Technologies Inc. Q3 FY2026 earnings call

• Strategic Execution & Heartbeat: Management emphasized the 'Heartbeat' operational framework, focusing on safety, quality, delivery, cost, and innovation. This has led to standardized work and daily management cadences, particularly in PCS, which resolved prior supply challenges and improved backlog conversion.
• Product Innovation & Regulatory Milestones: Key regulatory achievements include CE marking for the Photonova Spectra photon-counting CT system and pending FDA clearance for Star Guide GX. New ultrasound platforms were launched for cardiovascular, women’s health, and general imaging.
• Supply Chain Resilience: GE HealthCare entered multi-year strategic agreements with technology partners to secure memory chips, ensuring supply chain resiliency amid high cross-industry demand for advanced computing components. This aims to mitigate inflationary pressures and ensure predictable delivery.
• Leadership Changes: Jeannette Bankes stepped down as CEO of PCS to take a non-competitive CEO role elsewhere. Neil Sandy, currently head of product strategy and management for PCS, was appointed as her successor, bringing over 30 years of industry experience.
• Sophie Biosciences Acquisition: Announced plans to acquire Sophie Biosciences to establish a 'final mile' footprint for U.S. pet radiopharmaceutical supply. This strengthens the pipeline with FAPI 74 (a Phase III PET tracer) and enhances control over short-half-life radiopharmaceutical manufacturing.

Advanced Imaging Solutions: Organic revenue grew 4.5%, driven by strength in CT, cardiovascular/interventional solutions, and surgical innovations. EBIT margin expanded 130 basis points year-over-year, supported by volume, reduced tariff expenses, and pricing actions, partially offset by inflationary costs.

Pharmaceutical Diagnostics (PDX): Delivered robust organic revenue growth of 13.8%, contributed by contrast media and radiopharmaceuticals. Segment EBIT margin expanded 50 basis points to 29.9%, driven by volume and price, though partially offset by planned investments in new products and the innovation pipeline. The upcoming acquisition of Sophie Biosciences is expected to add approximately 1% of total company revenue on an annualized basis.

Patient Care Solutions (PCS): Organic revenue grew 8.8%, reflecting significant sequential improvement due to better operational performance, including improved product fulfillment in monitoring and maternal/infant care. Backlog continues to grow alongside revenue. Segment EBIT margin expanded 480 basispoints year-over-year, primarily driven by higher volume and cost productivity. Performance was aided by daily management improvements, though Q4 2025 included a one-time $45 million benefit from a product hold release.

• Organic Revenue Growth: Raised full-year 2026 guidance to approximately 4% organic revenue growth.
• Adjusted EBIT Margin: Raised full-year adjusted EBIT margin expectation to a range of 15.5% to 15.7%.
• Adjusted EPS: Raised full-year adjusted EPS guidance to a range of $4.95 to $5.05 per share.
• Free Cash Flow: Raised full-year free cash flow guidance to exceed $1.6 billion.
• Tax Rate & FX: Adjusted effective tax rate expected to be 20%–21%; forward exchange tailwind to revenue estimated at approximately 75 basis points.
• Q4 Context: Implied Q4 growth of 3%–4% reflects a base effect from PCS (due to the prior year's product hold catch-up) rather than market deceleration, with AIS and PDX driving top-line growth.

• Tariff Uncertainty: While current tariffs are lower than the prior year, Section 232 tariffs remain a significant swing item. Management is preparing for potential increased rates through pricing, cost productivity, and shifting some manufacturing scenarios to different countries.
• Inflationary Pressures: Costs for memory chips and higher oil prices across the supply chain negatively impacted margins, despite mitigation efforts.
• Supply Chain Constraints: Historically, supplier issues in PCS caused fulfillment delays, though recent operational improvements have mitigated this risk. Continued reliance on external suppliers for critical components like memory chips remains a vulnerability.
• Generic Competition in PDX: The contrast media market faces generic competition. While the market is growing, entry of new generic players could impact pricing power, though GE HealthCare believes its diversified portfolio and integration capabilities provide resilience.

Q: Analyst asked about the capital expenditure environment and whether procedure pullbacks or macro factors are impacting equipment budgets.

A: Management stated that imaging technologies remain top-of-mind for CFOs, with survey data showing sustained positive focus. No evidence of procedure slowdowns has been seen in scan or contrast use data yet. Capital equipment decisions often have long lead times (12-24 months), and the order funnel remains strong heading into Q4 and 2027.

Q: Analyst inquired about the path to a $500 million run rate for Felcoato by end of 2028 and how the Sophie acquisition aids this.

A: Management expressed confidence in the $500 million target, citing broad-based growth in both PET users and SPECT-to-PET converters. The Sophie acquisition expands the 'final mile' distribution network, crucial for short-half-life radiopharmaceuticals, enhancing supply reliability and allowing deeper participation in the ecosystem beyond just manufacturing.

Q: Analyst questioned the guidance implications for 2027, specifically regarding tariff refunds and if strong order growth will accelerate sales.

A: Management noted that while 2027 guidance comes in February, momentum is expected to continue. Tariff impacts are dynamic; however, the company is well-positioned with cost productivity and pricing actions. Q4 implied growth reflects a PCS base effect (prior year's hold catch-up) rather than deceleration, with AIS and PDX driving growth.

Q: Analyst asked about the sustainability of PCS's strong quarter versus one-time items and what drove the shift.

A: Management clarified that the improvement is underlying, not one-time. It stems from installations moving to H2 as planned and resolving supplier issues via 'Heartbeat' daily management. The team shifted to a weekly/daily cadence to address parts/component gaps immediately, expecting continued improvement into 2027.

Q: Analyst asked about the impact of generic Omnipaque competitors and PDX's ability to maintain high-single-digit growth.

A: Management highlighted that the contrast media market is already highly competitive with multiple players. Demand is near equilibrium with supply, and any new generic entrant will likely absorb unmet demand rather than solely stealing GE's share. The broader market is expected to double in 7-10 years, supporting PDX's growth trajectory.